Purpose: To determine the proportion of patients receiving hypnotics upon admission to a palliative care unit, the frequency and intensity of withdrawal symptoms after rapid hypnotic discontinuation, and the effect of discontinuation on insomnia and cognitive failure.
Introduction
Hypnotic drugs are considered useful in the treatment of transient (2-3 days) insomnia. These drugs may also be used on an intermittent basis and as adjunctive treatment in both short-term (<3 weeks) and chronic (>3 weeks) insomnia [1] . Long term use of hypnotics is frequently associated with excessive sedation and cognitive failure [2, 3] . These effects are more common among elderly patients (PTS) [4] . Advanced cancer PTS frequently develop cognitive failure even when they are not receiving hypnotics [5] . The purpose of this prospective open study was to determine the proportion of PTS receiving hypnotics upon admission to a palliative care unit, the number of PTS and families who accepted hypnotic discontinuation, the frequency and intensity of withdrawal symptoms, and the effect of rapid discontinuation on insomnia and cognitive function.
Patients and methods
One hundred and twenty consecutive PTS (mean age 62; standard deviation, SD -12; 62 females) with terminal cancer (defined as locally recurrent or metastatic cancer showing no response to antineoplastic therapy) were admitted to the Palliative Care Unit, Edmonton General Hospital between April 1990 and February 1991. PTS were admitted to this tertiary referral unit for the management of different symptoms associated with advanced cancer. One hundred and twelve PTS were admitted from acute care hospitals (93%) and 8 PTS from home (7%). All PTS were receiving opioid analgesics for cancer pain and were considered to be alert and able to communicate with the admitting physician. Upon admission, all PTS and available family were assessed by one of the investigators and were provided information on the management of chronic insomnia. They were told that unless they refused, we would attempt to discontinue all hypnotic therapy rapidly. The mean equivalent hypnotic starting dose per night was calculated for all hypnotics according to the Canadian Pharmaceutical Manual [6] . If a patient was receiving up to the equivalent starting daily dose of a certain hypnotic, the hypnotic was discontinued. If the dose was higher than the one proposed by the Canadian Pharmaceutical Manual, the dose was reduced by 50% every 24-48 hours attempting to complete discontinuation of the drug in approximately 4 days. If a patient refused to reduce or discontinue hypnotics he/she was maintained at the same dose they were receiving upon admission. PTS were assessed daily for signs of withdrawal. Mild withdrawal was defined as the presence of increased restlessness, anxiety, profuse sweating, tremors, increased sensitivity to taste, smell or light, or nightmares. Severe withdrawal was diagnosed as severe agitation, delirium, hyperthermia, or grand mal seizures. If withdrawal was detected, hypnotic dose was re-increased and an attempt for slower discontinuation was made.
A complete assessment of the severity of insomnia was performed during days 1, 4 and 7. This included visual analogue scales (0 -best symptom control, 100 -worst symptom control) for intensity of insomnia, restedness during the morning and difficulty falling asleep. In addition, a global rating of the intensity of insomnia was completed by the patient (0 -no importance; 1 -slight importance; 2 -some importance, consistent problem; 3 -moderate importance, consistent problem; 4 -much importance, good deal of a problem; 5 -very important; 6 -great importance.
All [7] . The daily dose of opioid analgesics were expressed as the mean equivalent daily dose of parenteral morphine [8] . The results of the insomnia and cognitive assessments in PTS who received hypnotics versus those who did not receive hypnotics were analyzed using two-tailed non-paired 1' test Changes in the results of different assessments over time in the same group of PTS were analyzed using two-tailed paired V tests. Proportions were compared using chi-square test. Data were analyzed according to the Statistical Package for the Social Sciences [9] .
Ninety-two/one hundred and twenty PTS (77%) had been receiving hypnotics for an average of 11 ± SD 8 weeks upon admission. The hypnotics were lorazepam (35 PTS), triazolam (22 PTS), chloral hydrate (11 PTS), temazepam (11 PTS), flurazepam (7 PTS), clonazepam (3 PTS) and diazepam (3 PTS), respectively. The mean equivalent hypnotic dose per night was 1.6 (SD-1). Four/ninetytwo PTS (4%) receiving hypnotics refused to discontinue or reduce their daily dose. Two/eighty-eight PTS (2%) in whom discontinuation was attempted presented with mild acute withdrawal symptoms that required a re-increase in the dose of hypnotic; both of these PTS could ultimately discontinue benzodiazepines. No PTS developed severe withdrawal.
There was no significant difference in the visual analogue scale or global rating for insomnia between the 92 PTS receiving hypnotics and the 28 PTS who were not receiving hypnotics upon admission. The 88 PTS in whom hypnotics were discontinued presented no significant change by day 4 and a decrease by day 7 in the intensity of insomnia, and showed a significant improvement in cognition during days 4 and 7 as compared to day 1, respectively (Table 1) . Before hypnotic discontinuation, 13/88 PTS rated their insomnia as Very important' or of 'great importance' (15%). After the discontinuation of hypnotics, 11/88 PTS scored insomnia as 'very important' or of 'great importance' (13%). 
Discussion
Our results suggest that a large proportion of cancer PTS continue to receive significant doses of hypnotic drugs for considerable periods of time. The overwhelming majority of PTS were quite willing to attempt hypnotic discontinuation after a brief explanation that usually lasted less than 10 minutes. The improvement in cognition in PTS who underwent hypnotic discontinuation cannot be solely ascribed to the hypnotic discontinuation since PTS also underwent other therapeutic interventions such as change in the type or route of opioids, hydration, and the management of metabolic or infectious complications. However, hypnotics had probably no beneficial effects in our population since they could be discontinued without significant worsening of the insomnia.
While there is considerable evidence that cancer PTS receive sub-optimal doses of opioids for cancer pain [10] , our data suggest that these PTS receive excessive treatment with hypnotics for longer periods of time than recommended. In the treatment of chronic cancer pain physicians have a trend to apply misconceptions about the toxicity of opioids that apply to acute shortterm therapy such as severe sedation, respiratory depression, or addiction. They may also carry misconceptions on the efficacy and safety of benzodiazepines from the acute, short-term treatment of insomnia into this very ill and frequently polymedicated population. These results identify an area where further medical education should take place.
